NFKB1 and thrombotic microangiopathy: Similarly, carfilzomib is associated to thrombotic microangiopathy likely due to excessive complement activation, reduction of vascular endothelial growth factor (VEGF) levels via NF-κB inhibition and endothelial injury (17).